Literature DB >> 15801011

Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis.

Frederick Wolfe1, Kaleb Michaud, Vibeke Strand.   

Abstract

OBJECTIVE: Minimally clinically important differences (MCID) have become an important way to interpret data of randomized clinical trials (RCT), but do not reflect the degree of improvement consistent with a "really important difference" (RID). To define RID, we compared mean and/or least desirable clinical states with best and/or most desirable states.
METHODS: In total, 8931 patients with rheumatoid arthritis (RA) < 65 years of age completed the Health Assessment Questionnaire (HAQ) and Medical Outcomes Survey Short Form 36 Physical Component Score (PCS). Definitions of RID were based on values for HAQ and PCS corresponding with the best and worst category of the following conditions: disabled vs not disabled: joint replacement vs no joint replacement; < poverty level vs > poverty level; very satisfied with health vs not; and independent in participation activities vs not.
RESULTS: In contrast to published MCID values for the HAQ of approximately 0.22, RID was as high as 0.76 using objective reference conditions and 0.87 using the subjective measure of dependence vs independence. The HAQ score of independent RA patients was 0.38 (SD 0.45), and was 0.42 (SD 0.53) for those very satisfied with their health. The difference in HAQ scores between disabled and working patients was approximately 0.75. PCS differences were similarly increased.
CONCLUSION: RID values are 3 to 4 times greater than MCID values. Although MCID are meaningful statistics for RCT, the RID percentage achieved [(actual improvement/RID) 100%] is a simple way to put the results of RCT in a broader perspective that gives an idea of how much additional treatment effect is needed.

Entities:  

Mesh:

Year:  2005        PMID: 15801011

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy.

Authors:  J T Langfitt; B G Vickrey; M P McDermott; S Messing; A T Berg; S S Spencer; M R Sperling; C W Bazil; S Shinnar
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

Review 2.  Exploring the diversity of conceptualizations of work (dis)ability: a scoping review of published definitions.

Authors:  Valérie Lederer; Patrick Loisel; Michèle Rivard; François Champagne
Journal:  J Occup Rehabil       Date:  2014-06

3.  Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study.

Authors:  Emilia Gvozdenović; Linda Dirven; Marianne van den Broek; K Huub Han; Esmeralda T H Molenaar; Robert B M Landewé; Willem F Lems; Cornelia F Allaart
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

4.  Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.

Authors:  Jasvinder A Singh; Shuo Yang; Vibeke Strand; Lee Simon; Anna Forsythe; Steve Hamburger; Lang Chen
Journal:  Ann Rheum Dis       Date:  2011-07       Impact factor: 19.103

5.  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

Authors:  N Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

6.  Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort.

Authors:  Michael Lukasiewicz; Stephanie Gerard; Adeline Besnard; Bruno Falissard; Elena Perrin; Helene Sapin; Mauricio Tohen; Catherine Reed; Jean-Michel Azorin
Journal:  Int J Methods Psychiatr Res       Date:  2013-03-21       Impact factor: 4.035

7.  Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Authors:  Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

8.  Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach.

Authors:  Henrica C W de Vet; Raymond W J G Ostelo; Caroline B Terwee; Nicole van der Roer; Dirk L Knol; Heleen Beckerman; Maarten Boers; Lex M Bouter
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 4.147

9.  Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.

Authors:  N Lynn Henry; Jon T Giles; Dennis Ang; Monika Mohan; Dina Dadabhoy; Jason Robarge; Jill Hayden; Suzanne Lemler; Karineh Shahverdi; Penny Powers; Lang Li; David Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo; Daniel J Clauw
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

10.  Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.

Authors:  Cosimo Bruni; Roberta Bitti; Francesca Nacci; Laura Cometi; Lorenzo Tofani; Francesca Bartoli; Ginevra Fiori; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2020-06-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.